Global Chronic Thromboembolic Pulmonary Hypertension Market Size By Type (Transthoracic Echocardiogram (TTE), Ventilation-Perfusion (V/Q) Scan), By Application (Hospitals, Ambulatory Surgical Centers)...

The Global Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Market was valued at USD 1.05 billion in 2023 and is projected to reach USD 2.18 billion by 2031, growing at a CAGR of 9.4% during the forecast period from 2023 to 2031. The market is primarily driven by the increasing prevalence of pulmonary hypertension conditions, advancements in diagnostic tools and therapeutic interventions, and rising awareness about rare cardiopulmonary disorders. CTEPH, a potentially curable form of pulmonary hypertension, often develops after pulmonary embolism and requires timely diagnosis and treatment, thereby propelling demand for specialized therapies, surgical interventions like pulmonary endarterectomy (PEA), and targeted drugs such as riociguat.

Drivers:

1. Rising Prevalence of Pulmonary Embolism and Hypertension Disorders:

An increasing number of pulmonary embolism cases globally is contributing to the prevalence of CTEPH, with more patients progressing into chronic stages requiring advanced treatments.

2. Advancements in Diagnostic Imaging and Intervention:

Technological improvements in imaging techniques, such as V/Q scanning, CT pulmonary angiography, and right heart catheterization, have enhanced early diagnosis and staging of CTEPH, facilitating prompt clinical decisions.

3. Introduction of Targeted Pharmacological Therapies:

Drugs like soluble guanylate cyclase (sGC) stimulators (e.g., riociguat) have shown clinical efficacy in inoperable cases or persistent CTEPH post-surgery, expanding treatment options and boosting pharmaceutical segment growth.

Restraints:

1. High Cost of Surgical and Drug-based Treatments:

CTEPH treatments, especially surgical procedures like PEA and lifelong medication, are associated with significant healthcare costs, limiting accessibility in low-resource settings.

2. Limited Diagnostic Awareness and Infrastructure in Developing Regions:

Delayed diagnosis due to lack of awareness and inadequate access to specialized pulmonary hypertension centers remains a challenge, particularly in emerging economies.

Opportunity:

1. Increasing Clinical Trials and Drug Approvals:

Ongoing clinical trials targeting newer drug classes, including tyrosine kinase inhibitors and endothelin receptor antagonists, offer immense potential for expanding therapeutic landscapes.

2. Rising Investments in Rare Disease Research:

Growing government and private sector focus on orphan disease research is likely to unlock innovation in CTEPH treatment approaches, including non-invasive modalities and novel biomarkers.

3. Emerging Markets and Improved Reimbursement Policies:

Expanding healthcare infrastructure and evolving reimbursement frameworks in Asia-Pacific and Latin America present lucrative opportunities for market players to penetrate underdeveloped regions.

Market by System Type Insights:

By treatment type, the Pharmacological Therapy segment dominated the market in 2023. Riociguat remains the only approved drug specifically indicated for CTEPH, driving demand in cases unsuitable for surgery or with persistent post-operative symptoms. However, the Surgical Treatment segment, led by Pulmonary Endarterectomy, is anticipated to witness robust growth due to its curative potential and increasing referrals to expert centers.

Market by End-use Insights:

Based on end use, Hospitals & Surgical Centers held the largest share in 2023 due to their role in advanced diagnosis and complex surgical procedures like PEA. The Specialty Clinics segment is expected to expand significantly as awareness of CTEPH-specific diagnostic pathways and follow-up care increases.

Market by Regional Insights:

North America accounted for the largest share of the global CTEPH market in 2023, owing to its robust healthcare system, high diagnostic rates, and established presence of major pharmaceutical companies. However, Asia-Pacific is projected to witness the highest CAGR during the forecast period due to improving healthcare access, rising disease awareness, and increased adoption of advanced treatments in countries like China, Japan, and India.

Competitive Scenario:

Prominent players in the Global CTEPH Market include Bayer AG, Merck & Co., Inc., United Therapeutics Corporation, Johnson & Johnson (Janssen Pharmaceuticals), and Pfizer Inc. These companies are investing in R&D, conducting clinical trials, and expanding their geographic reach to solidify market share.

Key Market Developments:

2023: Bayer AG expanded access programs for riociguat in Latin America, supporting patients in resource-limited regions.

2024: United Therapeutics initiated Phase II trials for a novel inhaled vasodilator targeting inoperable CTEPH cases.

2025: Janssen Pharmaceuticals announced collaborations with imaging centers to improve early detection of CTEPH using AI-assisted scans.

Scope of Work – Global Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Market

Report Metric Details

Market Size (2023) USD 1.05 billion

Projected Market Size (2031) USD 2.18 billion

CAGR (2023-2031) 9.4%

Market Segments By Treatment Type (Pharmacological, Surgical), By End-use (Hospitals, Specialty Clinics), By Region

Growth Drivers Rising prevalence of pulmonary embolism, advancements in imaging and drug therapies

Opportunities Drug innovation, increased funding for rare disease research, expanding access in emerging markets

FAQs:

1) What is the current market size of the Global Chronic Thromboembolic Pulmonary Hypertension Market?

The market was valued at USD 1.05 billion in 2023.

2) What is the major growth driver of the Global Chronic Thromboembolic Pulmonary Hypertension Market?

The primary growth driver is the increasing prevalence of pulmonary embolism and chronic pulmonary hypertension conditions.

3) Which is the largest region during the forecast period in the Global Chronic Thromboembolic Pulmonary Hypertension Market?

North America is projected to remain the largest regional market due to its advanced diagnostic and therapeutic infrastructure.

4) Which segment accounted for the largest market share in the Global Chronic Thromboembolic Pulmonary Hypertension Market?

Pharmacological Therapy, particularly the use of riociguat, accounted for the largest market share in 2023.

5) Who are the key market players in the Global Chronic Thromboembolic Pulmonary Hypertension Market?

Key players include Bayer AG, United Therapeutics Corporation, Janssen Pharmaceuticals, Merck & Co., Inc., and Pfizer Inc.